Early Access — free while we kick the tires
EdgarHawk

Myers Michael

Chief Executive Officer

Director Officer
2 filings analyzed · 1 company · Latest 2024-12-27

Companies

Company Buys Sells Direction
Quoin Pharmaceuticals, Ltd. QNRX 5 0 Net buying

Activity

December 2024
high
Buy
555,556 shares
$250,000
Significance 8/10

CEO Myers buys 555,556 shares at $0.45 for $250,000.20; stock down 89.3% from 52-week high; cluster buy pattern detected

Myers Michael, CEO of QNRX, purchased 555,556 shares at $0.45 on 2024-12-23, expanding his holdings by 1175.7% from 47,252 to 602,808 shares—a substantial concentration increase at a price 89.3% below the 52-week high of $180.14. His prior four purchases at QNRX all generated positive 90-day returns (ranging from 3494.8% to 4271.0%), establishing a pattern of well-timed entry points at this ticker. The company is currently unprofitable with net income of -$2,349,885.00 over its most recent full fiscal year, and this buy is part of a broader cluster pattern with 3 other insiders also purchasing within the past 14 days. The convergence of extreme price weakness, the CEO's significant position increase, his demonstrated track record of well-timed purchases at QNRX, and coordinated insider accumulation warrant close examination of the fundamental catalyst that may have prompted this coordinated action.

September 2024
medium
Buy
37,894 shares
$28,916
Significance 2/10

CEO Myers buys 37,894 shares across 4 transactions (Sep 3–4) for $28,916.10 at avg $0.76; stock now $27.91 post 45.8% 30-day rise from depressed levels.

Michael Myers, Chief Executive Officer, executed four separate purchases totaling 37,894 shares for $28,916.10 between September 3-4, 2024, at prices ranging from $0.62 to $0.80, expanding his holdings by 404.9% from 9,358 to 47,252 shares. The company is currently unprofitable with net income of $-1,974,033.00 over its most recent fiscal year, and the stock is -87.0% below its 52-week high of $215.60, though it has recovered +45.8% over the past 30 days. The magnitude and concentrated timing of this CEO purchase across four separate transactions provides a substantive data point on insider capital allocation in a deeply distressed equity, but the negative fundamentals and extreme drawdown from prior peaks limit the confidence signal.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access